TERN
Terns Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.11B
P/E Ratio
—
EPS
$-1.03
Beta
-0.38
52W High
$53.19
52W Low
$2.65
50-Day MA
$48.40
200-Day MA
$27.04
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other chronic liver diseases. The company is headquartered in Foster City, California.
Fundamentals
| Revenue (TTM) | $1.00M |
| Gross Profit (TTM) | $1.00M |
| EBITDA | $-110.03M |
| Operating Margin | 0.00% |
| Return on Equity | -14.20% |
| Return on Assets | -9.91% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $8.96 |
| Price-to-Book | 6.07 |
| Price-to-Sales (TTM) | 302.64 |
| EV/Revenue | 337.47 |
| EV/EBITDA | -5.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $115.52M |
| Float | $115.12M |
| % Insiders | 0.25% |
| % Institutions | 110.02% |
Historical Volatility
HV 10-Day
1.69%
HV 20-Day
2.10%
HV 30-Day
20.63%
HV 60-Day
35.82%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($53.00 target)
3
Buy7
HoldData last updated: 4/30/2026